×
About 4,400 results

ALLMedicine™ Acromegaly Center

Research & Reviews  1,438 results

Second line treatment of acromegaly: Pasireotide or Pegvisomant?
https://doi.org/10.1016/j.beem.2022.101684
Best Practice & Research. Clinical Endocrinology & Metabo... Chiloiro S, Bianchi A et. al.

Aug 6th, 2022 - Acromegaly is a chronic disease with an increased mortality in case of persistently active disease. The treatment of acromegaly is mainly based on the surgical resection of the GH secreting pituitary tumor and, in cases with persistent disease, on...

Impact of the diagnostic delay of acromegaly on bone health: data from a real life and ...
https://doi.org/10.1007/s11102-022-01266-4
Pituitary Chiloiro S, Giampietro A et. al.

Aug 4th, 2022 - Acromegaly is a chronic disease with systemic complications. Disease onset is insidious and consequently typically burdened by diagnostic delay. A longer diagnostic delay induces more frequently cardiovascular, respiratory, metabolic, neuropsychia...

Genetic Studies of Insulin and Diabetes
https://clinicaltrials.gov/ct2/show/NCT00001987

Aug 4th, 2022 - Study Description: Insulin is the key hormone responsible for regulating the level of glucose in plasma. In several disease states (e.g., obesity, type 2 diabetes, and acromegaly), the target cells are resistant to insulin action. Insulin resistan...

Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendo...
https://doi.org/10.1007/s40618-022-01875-7
Journal of Endocrinological Investigation; Machado-Alba JE, Machado-Duque ME et. al.

Aug 2nd, 2022 - Acromegaly and neuroendocrine tumors are rare diseases that, under certain conditions, can be treated with somatostatin analogs. The aim was to determine the prescription patterns of somatostatin analogs in a group of patients with acromegaly and ...

Compassionate Use of SOM230 for Hyperinsulinemic/Hypoglycemia
https://clinicaltrials.gov/ct2/show/NCT02835131

Jul 29th, 2022 - Congenital hyperinsulinism is a rare condition that can cause life-threatening hypoglycemia. Current treatment for congenital hyperinsulinism is often suboptimal, with diazoxide as the mainstay of treatment. Individuals who are not adequately trea...

see more →

Guidelines  5 results

Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) ...
https://doi.org/10.1016/j.numecd.2016.02.001
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD; Baroni MG, Giorgino F et. al.

Feb 26th, 2016 - Hyperglycemia is a common feature associated with states of increased growth hormone secretion and glucocorticoid levels. The purpose of these guidelines is to assist clinicians and other health care providers to take evidence-based therapeutic de...

Expert consensus document: A consensus on the medical treatment of acromegaly.
https://doi.org/10.1038/nrendo.2014.21
Nature Reviews. Endocrinology; Giustina A, Chanson P et. al.

Feb 26th, 2014 - In March 2013, the Acromegaly Consensus Group met to revise and update guidelines for the medical treatment of acromegaly. The meeting comprised experts skilled in the medical management of acromegaly. The group considered treatment goals covering...

American Association of Clinical Endocrinologists medical guidelines for clinical pract...
https://www.ncbi.nlm.nih.gov/pubmed/21846616
Endocrine Practice : Official Journal of the American Col... Katznelson L, Atkinson JL et. al.

Aug 24th, 2011 - American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update.|2011|Katznelson L,Atkinson JL,Cook DM,Ezzat SZ,Hamrahian AH,|diagnosis,therapy,standards,trends,...

AME Position Statement on clinical management of acromegaly.
https://www.ncbi.nlm.nih.gov/pubmed/19923883
Journal of Endocrinological Investigation; Cozzi R, Baldelli R et. al.

Jan 23rd, 2010 - AME Position Statement on clinical management of acromegaly.|2010|Cozzi R,Baldelli R,Colao A,Lasio G,Zini M,|diagnosis,economics,epidemiology,therapy,

Guidelines for acromegaly management: an update.
https://doi.org/10.1210/jc.2008-2421
The Journal of Clinical Endocrinology and Metabolism; Melmed S, Colao A et. al.

Feb 12th, 2009 - The Acromegaly Consensus Group reconvened in November 2007 to update guidelines for acromegaly management. The meeting participants comprised 68 pituitary specialists, including neurosurgeons and endocrinologists with extensive experience treating...

see more →

Drugs  27 results see all →

Clinicaltrials.gov  176 results

Genetic Studies of Insulin and Diabetes
https://clinicaltrials.gov/ct2/show/NCT00001987

Aug 4th, 2022 - Study Description: Insulin is the key hormone responsible for regulating the level of glucose in plasma. In several disease states (e.g., obesity, type 2 diabetes, and acromegaly), the target cells are resistant to insulin action. Insulin resistan...

Compassionate Use of SOM230 for Hyperinsulinemic/Hypoglycemia
https://clinicaltrials.gov/ct2/show/NCT02835131

Jul 29th, 2022 - Congenital hyperinsulinism is a rare condition that can cause life-threatening hypoglycemia. Current treatment for congenital hyperinsulinism is often suboptimal, with diazoxide as the mainstay of treatment. Individuals who are not adequately trea...

Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands
https://clinicaltrials.gov/ct2/show/NCT03967249

Jul 28th, 2022 - This extension study will include participants up to 60 participants with acromegaly from Study NCT03548415. All participants will remain on the same dose from the previous study and receive IONIS GHR-LRx (SC) injection once every 28 days as add-o...

A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
https://clinicaltrials.gov/ct2/show/NCT05364944

Jul 27th, 2022 - This is an open-label, single treatment arm, multicenter study to assess the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of Debio 4126 in the treatment of participants with Acromegaly or Functioning Gastroenteropancreati...

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
https://clinicaltrials.gov/ct2/show/NCT04076462

Jul 25th, 2022 - The purpose of this trial is to assess the efficacy and safety of CAM2029 in patients with acromegaly. Patients will be randomized to either CAM2029 or placebo administered subcutaneously once monthly during 6 months.

see more →

News  107 results

When to Treat Low Testosterone in Diabetes and Obesity
https://www.medscape.com/viewarticle/977284

Jul 15th, 2022 - Men with type 2 diabetes are at higher risk for testosterone deficiency. And in turn, hypogonadism is commonly associated with metabolic syndrome or type 2 diabetes. However, this does not imply a specific need for action, as Stephan Petersenn, MD...

Practice Guidelines Highlights From the Past Year
https://www.medscape.com/viewarticle/969871

Mar 8th, 2022 - Dr Douglas S. Paauw A 64-year-old woman is evaluated for fever, diarrhea, and abdominal pain. She was diagnosed with Clostridioides difficile 2 months ago and completed a 10-day course of vancomycin. Her stool toxin test is positive for Clostridio...

Practice guidelines highlights from past year
https://www.mdedge.com/internalmedicine/article/252401/infectious-diseases/practice-guidelines-highlights-past-year
Douglas S. Paauw, MD

Mar 3rd, 2022 - A 64-year-old woman is evaluated for fever, diarrhea, and abdominal pain. She was diagnosed with Clostridioides difficile 2 months ago and completed a 10-day course of vancomycin.

Oral Octreotide Shows Promise as Alternative to Injections for Acromegaly
https://www.medscape.com/viewarticle/966233

Jan 10th, 2022 - NEW YORK (Reuters Health) - Many patients with acromegaly may do as well on oral octreotide treatment as they do on injectable somatostatin receptor ligands (iSRLs), an industry-sponsored phase-3 trial suggests. Oral octreotide is the first oral m...

Association of Circulating IGF-I with Common Non-cancerous Conditions
https://www.medscape.com/viewarticle/963018

Nov 15th, 2021 - Takeaway Circulating insulin-like growth factor-I (IGF-I) was associated with several common conditions (other than cancer), including a positive association with carpal tunnel syndrome and inverse associations with varicose veins and iron deficie...

see more →

Patient Education  7 results see all →